How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center

Abstract

The availability of new biologic agents for the treatment of psoriasis provides hope for improved quality of life outcomes. However, the way patients come to use biologics, potential barriers they encounter, and their attitudes towards using these medications are still not well studied. Here, we conducted a survey of 106 psoriasis patients at an academic medical center to discern patient attitudes towards biologics. We found that most patients learn of biologics through their physician and perform follow-up research using the Internet. Most patients did not find it difficult to make the decision to start a biologic. Difficulty in obtaining biologics was associated with age less than 55 (p=0.01), lower income level (p=0.007), and lack of insurance (p=0.04). Patients were found to have high satisfaction and compliance rates on biologics. Of patients who missed a dose of their biologic, this was mainly due to logistical reasons such as not having the medication or forgetting to take it, rather than being depressed or overwhelmed. Patients with lower income levels had increased cutbacks in personal expenses due to co-payments (p=0.001). Among respondents, the mean annual out of pocket expense for a biologic was $557.12 per year, with a range of $0 to $7,000.

Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study

“…However, in our multivariable regression analyses, we controlled for various confounding factors so that such effects would be minimized and false interpretation could be avoided. Although different adherence measures were applied in other studies, limiting comparability with results from ALIGN, the percentages of patients with PS or CD treated with TNFi monotherapy and combination therapy who reported high adherence based on the MMAS-4 corresponded to the adherence levels for biologics reported in the same IMIDs by other authors [8, 45]. Another limitation is the cross-sectional rather than prospective design of this study.…”

A patient‐centred approach to biological treatment decision making for psoriasis: an expert consensus

“…A further 22 relevant associated articles were found. Excluding duplications, a total of 52 relevant articles were identified …”

Pediatric psoriasis: Evolving perspectives

“…Most studies in adults report low adherence rates (21.6%‐75%). Four studies found a positive association between treatment adherence and clinical improvement in psoriasis symptoms . Poor adherence to topical therapy is the most common cause of treatment failure.…”